GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: clifutinib | compound 9e [PMID: 40213868]
Compound class:
Synthetic organic
Comment: This is a tyrosine kinase inhibitor claimed in patent WO2016008433A1, in which it is proposed as a fms related receptor tyrosine kinase 3 (FLT3 inhibitor) with anti-leukemic potential [1]. It appears be the structure for HEC Pharma's FLT3 inhibitor named clifutinib (not an official INN) which is reported in [2].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Cheng C, Zhang Y, Liu B, Long B, Chern Y, Cheng Z. (2016)
ubstituted urea derivatives and pharmaceutical uses thereof. Patent number: WO2016008433A1. Assignee: Sunshine Lake Pharma Co., Ltd.. Priority date: 19/07/2015. Publication date: 21/01/2016. |
2. Liu B, Kang N, Yang F, Zhang W, Yan X, Wang H, Bai S, Cheng CC, Xu J, Hu W et al.. (2025)
Discovery of FLT3-ITD Inhibitor Clifutinib: A Novel Biphenylacetylene Urea Derivative in Clinical Trials for the Treatment of Relapsed/Refractory FLT3-ITD+ Acute Myeloid Leukemia. J Med Chem, 68 (8): 7955-7972. [PMID:40213868] |